{"id":"mci-186","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL3663480","moleculeType":"Small molecule","molecularWeight":"444.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MCI-186 (edaravone) acts as a potent antioxidant by scavenging free radicals, particularly hydroxyl radicals and peroxynitrite, which are implicated in neuronal damage. By reducing oxidative stress and subsequent neuroinflammation, it may limit the progression of neurodegeneration in acute ischemic stroke and amyotrophic lateral sclerosis (ALS). The drug crosses the blood-brain barrier and exerts neuroprotective effects during the acute phase of injury.","oneSentence":"MCI-186 is a free radical scavenger that neutralizes reactive oxygen species and reduces oxidative stress in neuronal tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:44.406Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Amyotrophic lateral sclerosis (ALS)"}]},"trialDetails":[{"nctId":"NCT04029090","phase":"PHASE1","title":"A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-09-18","conditions":"Healthy Adult Subjects","enrollment":27},{"nctId":"NCT07467746","phase":"PHASE2","title":"Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2026-04","conditions":"Amyotrophic Lateral Sclerosis","enrollment":84},{"nctId":"NCT07454473","phase":"PHASE4","title":"Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study","status":"RECRUITING","sponsor":"Chuansheng Zhao","startDate":"2026-03-02","conditions":"Chemo Brain","enrollment":80},{"nctId":"NCT03289208","phase":"PHASE1","title":"Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-10-27","conditions":"Renal Impairment, Healthy","enrollment":30},{"nctId":"NCT03664544","phase":"PHASE1","title":"PK Study in Subjects With Severe Hepatic Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-11-06","conditions":"Severe Hepatic Impairment, Healthy","enrollment":12},{"nctId":"NCT00821821","phase":"PHASE2","title":"Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-02","conditions":"Acute Ischemic Stroke (AIS)","enrollment":36},{"nctId":"NCT03346538","phase":"PHASE2","title":"Dose Finding Study of MCI-186 in Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-11-17","conditions":"Acute Ischemic Stroke","enrollment":17},{"nctId":"NCT03289234","phase":"PHASE1","title":"Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-11-16","conditions":"Hepatic Impairment, Healthy","enrollment":22},{"nctId":"NCT00200356","phase":"PHASE4","title":"Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2004-08","conditions":"Cerebral Infarction","enrollment":401},{"nctId":"NCT04481750","phase":"PHASE1","title":"Study of Oral Edaravone in Healthy Adult Males","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-03-20","conditions":"Healthy Adult Subjects","enrollment":74},{"nctId":"NCT04776135","phase":"PHASE1","title":"Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2021-02-26","conditions":"Healthy Adult Subjects","enrollment":36},{"nctId":"NCT05342597","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-06-10","conditions":"Healthy Adult Subjects","enrollment":16},{"nctId":"NCT04176224","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-17","conditions":"Japanese Patients With ALS","enrollment":9},{"nctId":"NCT04254913","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2020-01-24","conditions":"Japanese Patients With ALS","enrollment":6},{"nctId":"NCT04481789","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-10-17","conditions":"Healthy Adult Subjects","enrollment":84},{"nctId":"NCT04493281","phase":"PHASE1","title":"Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-03-22","conditions":"Healthy Adult Subjects","enrollment":42},{"nctId":"NCT01492686","phase":"PHASE3","title":"Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-12","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":137},{"nctId":"NCT00424463","phase":"PHASE3","title":"Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":181},{"nctId":"NCT00330681","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-05","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":206},{"nctId":"NCT00415519","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-12","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":25},{"nctId":"NCT04165824","phase":"PHASE3","title":"Safety Study of Oral Edaravone Administered in Subjects With ALS","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2019-11-18","conditions":"ALS","enrollment":185},{"nctId":"NCT05568615","phase":"PHASE3","title":"Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2022-10-26","conditions":"ALS","enrollment":15},{"nctId":"NCT04577404","phase":"PHASE3","title":"Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-10-29","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":124},{"nctId":"NCT05151471","phase":"PHASE3","title":"Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS","status":"TERMINATED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2022-01-11","conditions":"ALS","enrollment":202},{"nctId":"NCT04569084","phase":"PHASE3","title":"Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS","status":"TERMINATED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-11-13","conditions":"ALS","enrollment":384},{"nctId":"NCT06674460","phase":"PHASE3","title":"Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-08-01","conditions":"Cerebral Small Vessel Disease, Ischemic Stroke","enrollment":600},{"nctId":"NCT06315231","phase":"PHASE2","title":"Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients","status":"RECRUITING","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2024-04-08","conditions":"Post-stroke Cognitive Impairment","enrollment":226},{"nctId":"NCT07138014","phase":"PHASE2","title":"FHND1002 for ALS Treatment: Phase 2","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":180},{"nctId":"NCT07119021","phase":"PHASE4","title":"Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)","status":"RECRUITING","sponsor":"Ruijun Ji","startDate":"2024-08-01","conditions":"Ischemic Stroke","enrollment":300},{"nctId":"NCT07091994","phase":"PHASE4","title":"A Prospective, Multicentre, Randomized Controlled Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-08-01","conditions":"Ischemic Stroke, Acute, Active Malignancies","enrollment":144},{"nctId":"NCT04097158","phase":"","title":"Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone","status":"RECRUITING","sponsor":"Loma Linda University","startDate":"2019-10-08","conditions":"Amyotrophic Lateral Sclerosis","enrollment":160},{"nctId":"NCT05323812","phase":"PHASE2","title":"ASURE: Alzheimer Study Using oRal Edaravone","status":"COMPLETED","sponsor":"Treeway B.V.","startDate":"2023-03-01","conditions":"Alzheimer Disease","enrollment":61},{"nctId":"NCT05178810","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Ferrer Internacional S.A.","startDate":"2021-10-18","conditions":"Amyotrophic Lateral Sclerosis","enrollment":313},{"nctId":"NCT05540262","phase":"NA","title":"Edaravone in the Treatment of Optic Neuritis","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2022-01-15","conditions":"Optic Neuritis","enrollment":50},{"nctId":"NCT04370431","phase":"PHASE1","title":"A Study of TTYP01 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2020-04-24","conditions":"Healthy Adult Subjects","enrollment":72},{"nctId":"NCT06645522","phase":"PHASE4","title":"Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Yi Yang","startDate":"2024-10-30","conditions":"Acute Ischemic Stroke","enrollment":1200},{"nctId":"NCT06107205","phase":"PHASE1","title":"Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2023-11-07","conditions":"Healthy Adult Subjects","enrollment":29},{"nctId":"NCT05086874","phase":"","title":"Using Real-world Evidence to Analyze the Clinical Effects and Adverse Events of Butylphthalide in Stroke Patients","status":"COMPLETED","sponsor":"Xin Huang","startDate":"2022-05-07","conditions":"Stroke, Cerebral Infarction, Brain Infarction","enrollment":81292},{"nctId":"NCT04984577","phase":"PHASE2","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"SUSPENDED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2021-11-15","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT06248242","phase":"PHASE4","title":"Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol","status":"UNKNOWN","sponsor":"The Second Hospital of Hebei Medical University","startDate":"2021-06-01","conditions":"Acute Ischemic Stroke","enrollment":400},{"nctId":"NCT06176781","phase":"PHASE3","title":"The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-12-28","conditions":"Subjects With Acute Ischemic Stroke","enrollment":880},{"nctId":"NCT04202549","phase":"NA","title":"Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT)","status":"COMPLETED","sponsor":"Hui-Sheng Chen","startDate":"2019-12-15","conditions":"Ischemic Stroke","enrollment":30},{"nctId":"NCT05644223","phase":"","title":"Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-01-01","conditions":"Acute Ischemic Stroke","enrollment":4750},{"nctId":"NCT04259255","phase":"","title":"Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)","status":"UNKNOWN","sponsor":"Tanabe Pharma America, Inc.","startDate":"2019-10-21","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":300},{"nctId":"NCT05121883","phase":"","title":"Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-11-01","conditions":"Stroke","enrollment":200},{"nctId":"NCT05249920","phase":"PHASE3","title":"Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-03-18","conditions":"Acute Ischemic Stroke, Mechanical Thrombectomy, Edaravone Dexborneol","enrollment":1362},{"nctId":"NCT04950920","phase":"PHASE3","title":"Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2021-06-28","conditions":"Stroke","enrollment":914},{"nctId":"NCT05953103","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-07-03","conditions":"Subjects With Cerebral Hemorrhage","enrollment":380},{"nctId":"NCT05920902","phase":"","title":"Arterial Spin Label Depicted Ischemic Stroke Cohort (ASLIS)","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-10-01","conditions":"Acute Ischemic Stroke","enrollment":200},{"nctId":"NCT05885919","phase":"PHASE3","title":"Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2023-07-01","conditions":"Ischemic Stroke, Acute, Treatment Outcome","enrollment":212},{"nctId":"NCT04667637","phase":"PHASE2","title":"Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol","status":"COMPLETED","sponsor":"Hui-Sheng Chen","startDate":"2021-02-23","conditions":"Stroke, Endovascular Thrombectomy","enrollment":200},{"nctId":"NCT04817527","phase":"PHASE2","title":"Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-10-01","conditions":"Stroke, Ischemic","enrollment":200},{"nctId":"NCT05024526","phase":"NA","title":"Protective Effects of Edaravone Dexborneol","status":"UNKNOWN","sponsor":"Lili Cao","startDate":"2021-04-01","conditions":"Acute Ischemic Stroke","enrollment":80},{"nctId":"NCT05035953","phase":"PHASE2","title":"Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-09-13","conditions":"Stroke, Ischemic","enrollment":200},{"nctId":"NCT04219865","phase":"PHASE1","title":"Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection","status":"COMPLETED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-06-05","conditions":"Pharmacokinetics","enrollment":40},{"nctId":"NCT04218513","phase":"PHASE1","title":"Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection","status":"COMPLETED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-05-10","conditions":"Drug-drug Interaction","enrollment":24},{"nctId":"NCT04714177","phase":"PHASE2","title":"Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-03-01","conditions":"Intracerebral Hemorrhage","enrollment":390},{"nctId":"NCT03968042","phase":"PHASE2","title":"Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2019-06-30","conditions":"Alcohol-induced Brain Injury","enrollment":150},{"nctId":"NCT04391361","phase":"PHASE2","title":"The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-11-01","conditions":"Amyotrophic Lateral Sclerosis, Respiratory Function, Scopolamine","enrollment":30},{"nctId":"NCT03495206","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet","status":"UNKNOWN","sponsor":"Yantai YenePharma Co., Ltd.","startDate":"2018-10-25","conditions":"Stroke, Acute, Intracranial Hemorrhages","enrollment":24},{"nctId":"NCT03272802","phase":"PHASE2, PHASE3","title":"Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2017-03-16","conditions":"Neuromuscular Diseases","enrollment":20},{"nctId":"NCT02430350","phase":"PHASE3","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2015-05","conditions":"Acute Ischemic Stroke","enrollment":1200},{"nctId":"NCT02644915","phase":"NA","title":"Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2016-03","conditions":"Kidney Transplantation","enrollment":150},{"nctId":"NCT01929096","phase":"PHASE2","title":"Compound Edaravone Injection for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":"Acute Ischemic Stroke","enrollment":400},{"nctId":"NCT00265239","phase":"PHASE4","title":"Pilot Study of Edaravone to Treat Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2001-04","conditions":"Myocardial Infarction, Reperfusion Injury","enrollment":104},{"nctId":"NCT01894334","phase":"NA","title":"Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-04","conditions":"Acute Aortic Dissection","enrollment":220},{"nctId":"NCT01865201","phase":"PHASE2","title":"Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2009-03","conditions":"Nasopharyngeal Carcinoma, Brain Necrosis","enrollment":154},{"nctId":"NCT01556854","phase":"","title":"Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"yongjun wang","startDate":"2011-07","conditions":"Acute Ischemic Stroke","enrollment":20000},{"nctId":"NCT01518231","phase":"PHASE1","title":"Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke","status":"UNKNOWN","sponsor":"Zhejiang Hospital","startDate":"2012-01","conditions":"Stroke","enrollment":40},{"nctId":"NCT00153946","phase":"PHASE4","title":"Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Combination Therapy for Acute Ischemic Stroke Study Group","startDate":"2004-08","conditions":"Stroke","enrollment":814}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":120,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Edaravone","Radicut","Radicava"],"phase":"phase_3","status":"active","brandName":"MCI-186","genericName":"MCI-186","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MCI-186 is a free radical scavenger that neutralizes reactive oxygen species and reduces oxidative stress in neuronal tissue. Used for Acute ischemic stroke, Amyotrophic lateral sclerosis (ALS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}